Ask AI
ProCE Banner Activity

Key Updates in Lung Cancers From the ELCC 2024 Annual Meeting

Conference Coverage
Clinical Thought

Lung cancer experts highlight key studies from the 2024 European Lung Cancer Congress. CCO’s Independent Conference Coverage has the information you need to understand and integrate the latest data into your management of patients with NSCLC and SCLC.

Released: May 03, 2024

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc

Faculty Disclosure

Primary Author

Luis Paz-Ares, MD, PhD

Head of Medical Oncology Department
Hospital Universitario 12 de Octubre
Associate Professor, Universidad Complutense de Madrid
Madrid, Spain

Luís Paz-Ares, MD, PhD: honoraria: Amgen, AstraZeneca, Bayer, Beigene, Boehringer-Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Jazz Pharmaceuticals, Merck Serono, Mirati Therapeutics, Merck Sharp & Dohme, Novartis, Pfizer, PharmaMar, Roche/Genentech, Sanofi, Takeda; founder and board member: ALTUM Sequencing, Stab therapeutics; research funding (to Institution): AstraZeneca, Bristol Myers Squibb, Merck Sharp & Dohme, PharmaMar; speaker fees: Bristol Myers Squibb, Eli Lilly, Merck Serono, Merck Sharp & Dohme Oncology, Pfizer, Roche/Genentech.

Zofia Piotrowska, MD, MHS

Associate Professor of Medicine, Harvard Medical School
Clinical Co-Director, MGB Thoracic Medical Oncology Program
Mass General Brigham Cancer Institute
Boston, Massachusetts

Zofia Piotrowska, MD, MHS: consultant/advisor/speaker: AbbVie, AstraZeneca, Bayer, Blossom Hill Therapeutics, Boehringer Ingelheim, Daiichi Sankyo, Genmab, Gilead, Janssen, Lilly, Natera, Regeneron, Revolution Medicines, Summit, Taiho, Takeda, Tubulis; researcher: AbbVie, AstraZeneca, Blossom Hill Therapeutics, Blueprint Medicines, Cullinan Oncology, Daiichi Sankyo, Janssen, Novartis, Nuvalent, Spectrum, Systimmune, Takeda, Tesaro/GSK.